(HealthDay)—The recombinant influenza vaccine (RIV4) is well tolerated in children aged 6 to 17 years, and it provides immunogenicity comparable to that of the inactivated vaccine, according to a study published online ...
Apr 2, 2018
0
2
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza ...
May 17, 2013
1
0
Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according ...
May 22, 2012
0
0
When different types of cells are transplanted with the intent of having them aid in repairing central nervous system (CNS) trauma, what is the fate and function of those cells? A Belgian research team carried out research ...
Dec 20, 2012
0
0
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
May 22, 2013
0
0
Early results of a trial to treat leukaemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date.
Dec 7, 2012
0
0
(HealthDay)—Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric ...
Oct 16, 2012
0
0
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: ...
Aug 16, 2012
0
0
